Navigation Links
Italian Doctors To Operate On World's Fattest Man

40-year-old Manuel Uribe Garza, who weighs 550 kilos (1211.5 pounds) is to have a fat removal surgery in Italy. Garza is believed to be the fattest man in the world.// The Mexican is no longer able to move around and doctors say he is suffering from morbid obesity.

"We will hold a meeting in the coming days to work out the details of the hospitalization and to prepare the operating theater and the appropriate surgical tools," Head doctor Giancarlo DeBernardinis told the AFP. DeBernardinis visited his heavy patient in March this year and will again go to Mexico before giving the surgery a final thumbs-up. Garza has received a lot of dietary treatment, but despite that his condition remains the same. That is why his Italian doctor said that "in cases such as this one, there is no alternative but to operate." The main procedure will be to create "a series of short-circuits" in Uribe Garza's intestines, DeBernardinis said. This means that only 10 percent of whatever Garza eats will be absorbed.

"In two years, Uribe should have lost a substantial portion of his 550 kilos," he said.
RAS
'"/>




Page: 1

Related medicine news :

1. Electronic nose by Italian scientists
2. My Dad Is 100 Years Old; Italian Actress Rossellini in Trouble
3. Italian Court Presides Over the Judgment of Incurably Ill Italian Man, Pleading Euthanasia
4. Italian Who Met Former KBG Spy is Arrested
5. Italian Olives Recalled from Canada
6. Cancer Doctors Okays Controversial Prostate Therapy
7. Doctors needed urgently in Gujarat
8. Doctors operate upon patients in candlelight- latest from the quake scene
9. Doctors at risk- the ugly side of the noble profession
10. Doctors advice early anemia tests
11. Emphasis to ban Drugs ads by Doctors
Post Your Comments:
(Date:5/16/2008)...rstCall/ -- Tempo Participacoes,S.A. (Bovespa: TEM...ding,provider of healthcare administration service... services, announces today its results for the fir...formation contained herein,except where otherwise...,accordance with Brazilian Stock Exchange Commissi...
(Date:5/15/2008)...sing in Targeting Cancer Cells, ...ay 15 /PRNewswire-FirstCall/ -- Abbott scientists,...everal investigative,compounds in the company,s on... Clinical Oncology (ASCO) Annual Meeting, schedule... ABT-263, a Bcl-2 family protein,antagonist, and A...
(Date:5/15/2008)...ng cancer treatment for each individual, researche...resented a study suggesting a simple blood test ca...cacy for patients with metastatic breast cancer. ,...to determine if a particular cancer treatment is w...y significant radiographic changes in tumor size o...
(Date:5/15/2008)...tCall/ -- Digital Power,Corporation (Amex: DPW ) ...cial results for the first quarter ended March 31,...000 for the quarter ended,March 31, 2008, an incre...last year. An operating loss of $165,000 for the f...operating profit of $25,000 for the same quarter,l...
Breaking Medicine News(10 mins):Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 2Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 3Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 4Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 5Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 6Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 3
... North America with an estimated 400,000 people fa...of these //people have their hearts pumping again ...of the main causes of death after the heart is res...esented at the 2006 Society for Academic Emergency...
...cos here have collapsed due to fasting in the past...fight against// reservation for backward classes w...ecision. "Ninety-four doctors have so far collapse...e hunger strike. Currently 35 of them are still si...
...people to get themselves screened for HIV, city-ru...criteria// for HIV testing. According to the new r...ent is not neccessary for voluntary HIV/AIDS testi...consent from the patient. This rule makes it the ...
...e discovered the cause for people to overeat. Scie...it's in the brain//. Researchers at the council's... the first neurobiological proof as to why some pe...research, published today in the Journal of Neuros...
Other Medicine News:Health News:Survival After Cardiac Arrest Is Aided By Cooling 2Health News:Despite Collapse Of The Medicos Strike To Continue Unabated 2Health News:Research Scans Explain Why People Crave For Food 2
(Date:5/16/2008)...r Novel Approach to Blood ...wire-FirstCall/ -- Pharmacopeia (Nasdaq:,PCOP), an...el small,molecule therapeutics, announced today th...or Antagonist (DARA), showed statistically signifi... in patients with mild to,moderate hypertension. P...
(Date:5/15/2008)...- Eisai Corporation of North,America announced tod...out,compounds in the company,s oncology pipeline, ...h have been accepted for presentation at the,44th ... Oncology (ASCO),taking place in Chicago from May... on Eisai marketed products and,investigational co...
(Date:5/15/2008)...ety profile of BSI-201 in subjects...May 15 /- BiPar Sciences, Inc., a,pri...ovel cancer therapies,today announced that data s...e presented at the 2008 American Society of Clinic...will be presented from the first in human Phase 1 ...
(Date:5/15/2008)...rstCall/ -- Cytopia Limited,(ASX: CYT) today annou...ntation on CYT997 at the 2008 Annual Meeting of th...l be accessible to the public via ASCO,s,website ... (US EDT)., The oral presentation, entitled "Phas...scular disrupting agent, in patients with advanced...
Breaking Medicine Technology:Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Tata Consultancy Services to Support Roches Global Capacity Building Initiative 455 1Tata Consultancy Services to Support Roches Global Capacity Building Initiative 455 2Tata Consultancy Services to Support Roches Global Capacity Building Initiative 455 3Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 1Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 2Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 3Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 4Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 5Mega Events in September Allow Heart Health Campaign to Reach Tens of Thousands of Hispanics During Cholesterol Awareness Month 450 6Nanotechnology 3A Whats that 3F 244 1Nanotechnology 3A Whats that 3F 244 2Avocados may help prevent oral cancer OSU study shows 443 1Avocados may help prevent oral cancer OSU study shows 443 2
... in Evaluating Drug,Efficacy; Dr. H. Bryan Brewer,...EASANTON, CA, Mar 30, 2007 (MARKET WIRE via COMTEX...PD) Dr. H. Bryan Brewer, Jr.,Chief Scientific Dir...wide range of presentations at the recent American...s that the rationale for HDL,being the next, most ...
...al and Social,Performance, COLORADO SPRINGS, C... treatment with INVEGA(TM) (paliperidone),Extend...on for,schizophrenia, helped many patients effec... improvements in personal and social,functioning...el, international,clinical trial sponsored by Ja...
Other Medicine Technology:Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 2Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 3Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 4Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 5Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 2Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 3Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 4Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 5Study Suggests Invega Helps Patients With Schizophrenia Maintain,Symptom Control 6
...: The HF-compatible V series from Pentax, the stan...asured., ,The HF-compatible series of fibre bronc...V and FB-15V models along with the very slim FB-10... quality thanks mainly to the higher resolution an...
...m the latest 60 series bronchoscopes., ,Olymp... providing clinicians with superior specifications...ressive range of fiberoptic instruments for diagno...he demands of increasing peripheral bronchoscopy.,...
The BRO-YP2 is Fujinon's pediatric fiberoptic bronchoscope. Its small outside diameter allows for more comfortable transnasal insertion. The standard 2.0mm channel provides sufficient suction and acc
...m the latest 60 series bronchoscopes., ,Olymp... providing clinicians with superior specifications...ressive range of fiberoptic instruments for diagno...he demands of increasing peripheral bronchoscopy.,...
Medicine Products: